GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cyclo Therapeutics Inc (NAS:CYTH) » Definitions » Financial Strength

Cyclo Therapeutics (Cyclo Therapeutics) Financial Strength : 3 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cyclo Therapeutics Financial Strength?

Cyclo Therapeutics has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Cyclo Therapeutics Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Cyclo Therapeutics's interest coverage with the available data. Cyclo Therapeutics's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.83. As of today, Cyclo Therapeutics's Altman Z-Score is -10.44.


Competitive Comparison of Cyclo Therapeutics's Financial Strength

For the Drug Manufacturers - Specialty & Generic subindustry, Cyclo Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclo Therapeutics's Financial Strength Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cyclo Therapeutics's Financial Strength distribution charts can be found below:

* The bar in red indicates where Cyclo Therapeutics's Financial Strength falls into.



Cyclo Therapeutics Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Cyclo Therapeutics's Interest Expense for the months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the months ended in Dec. 2023 was $-5.64 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.02 Mil.

Cyclo Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Cyclo Therapeutics's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Cyclo Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Cyclo Therapeutics's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.011 + 0.022) / 1.244
=0.83

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Cyclo Therapeutics has a Z-score of -10.44, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -10.44 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclo Therapeutics  (NAS:CYTH) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Cyclo Therapeutics has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Cyclo Therapeutics Financial Strength Related Terms

Thank you for viewing the detailed overview of Cyclo Therapeutics's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclo Therapeutics (Cyclo Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6714 North West 16th Street, Suite B, Gainesville, FL, USA, 32653
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company develops cyclodextrin-based products for the treatment of disease. Its drug candidate, Trappsol Cyclo, treats Niemann-Pick Type C disease (NPC). Its other products include Trappsol HPB, Trappsol Fine Chemical, and Aquaplex.
Executives
Vivien Wong director 6C CHATEAUX CIRCLE, SCARSDALE NY 10583
Rafael Holdings, Inc. 10 percent owner 520 BROAD STREET, NEWARK NJ 07120
William Conkling director C/O RAFAEL HOLDINGS, INC., 520 BROAD ST, NEWARK NJ 07102
Jeffrey Tate director, officer: Chief Executive Officer C/O CTD HOLDINGS, INC., 27317 NW 78TH AVENUE, HIGH SPRINGS FL 32643
Francis Patrick Ostronic director 932 HUNGERFORD DRIVE, SUITE 28A, ROCKVILLE MD 20850
Markus Sieger director BEUTSTWEG 12, CH-8032, ZURICH V8 000000000
N Scott Fine director 600 3RD AVE, NEW YORK NY 10016
Sharon Hemond Hrynkow officer: SVP for Medical Affairs 4816 KING SOLOMON DRIVE, ANNADALE VA 22003
Lise Lund Kjems officer: Chief Medical Officer 91 ROLLINGWOOD LN., CONCORD MA 01742
Joshua M Fine officer: Chief Financial Officer 21 HEMMELSKAMP ROAD, WILTON CT 06897
Armistice Capital Master Fund Ltd. 10 percent owner C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Michael Eric Lisjak officer: Chief Regulatory Officer 12 ROOSEVELT AVENUE, OLD GREENWICH CT 06870
Steven Boyd 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc 10 percent owner 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
L.p. Novit, 10 percent owner 966 HUNGERFORD DRIVE, ROCKVILLE MD 20850

Cyclo Therapeutics (Cyclo Therapeutics) Headlines